

Regulatory Announcement

Go to market news section



Company Fulcrum Pharma PLC
TIDM FUL
Headline Proposed Board Changes
Released 07:01 10-Jan-08
Number 4614L

.fulcrum>

RNS Number:4614L
 Fulcrum Pharma PLC
 10 January 2008

Final

10th January 2008

FULCRUM PHARMA PLC
 ("the Company")

Succession planning for growth and integration of European businesses for improved profitability

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, announces that Jon Court, Chief Executive Officer, has indicated his desire to step down as Chief Executive. Fulcrum has grown from a small UK business of under 10 people at the time of its listing on AIM in 2000 to one with offices on 3 continents, with over 150 employees and revenues of £11.5M. Dr Court considers that the Company's long term prospects will be better served by the appointment of a Chief Executive with the experience of managing a large, multinational business. The Board has accepted Dr Court's wishes and the process of searching for a new Chief Executive has commenced.

In addition to these succession plans, the Board is preparing the Company for its next growth phase. Dr Angus Bell, non executive director, has been appointed to lead the integration of its businesses in Europe to improve profitability and enable further expansion through organic growth and M&A activity.

Dr Court will remain with the company in a business development and client project role focussing on long term client relationships.

Jon Court, Chief Executive of Fulcrum Pharma, said: "Fulcrum has changed substantially from when I co-founded the business in 2000. I now feel that the time has come for Fulcrum to appoint a new chief executive with the requisite skills and background to take the business further forward. I remain, however, fully committed to Fulcrum and look forward to working closely with Dr Bell and the new chief executive once he or she is appointed"

For further information, please contact:

Fulcrum Pharma PLC
 Jon Court, Chief Executive Tel: 0870 710 7152

Seymour Pierce
 Jonathan Wright Tel: 0207 107 8000

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that

provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2008 London Stock Exchange plc. All rights reserved